t e c h n i c a l r e p o r t s Immunodominance is defined as restricted responsiveness of T cells to a few selected epitopes from complex antigens. Strategies currently used for elucidating CD4 + T cell epitopes are inadequate. To understand the mechanism of epitope selection for helper T cells, we established a cell-free antigen processing system composed of defined proteins: human leukocyte antigen-DR1 (HLA-DR1), HLA-DM and cathepsins. Our reductionist system successfully identified the physiologically selected immunodominant epitopes of two model antigens: hemagglutinin-1 (HA1) from influenza virus (A/Texas/1/77) and type II collagen (CII). When applied for identification of new epitopes from a recombinant liverstage antigen of malaria falciparum (LSA-NRC) or HA1 from H5N1 influenza virus ('avian flu'), the system selected single epitopes from each protein that were confirmed to be immunodominant by their capacity to activate CD4 + T cells from H5N1-immunized HLA-DR1-transgenic mice and LSA-NRC-vaccinated HLA-DR1-positive human volunteers. Thus, we provide a new tool for the identification of physiologically relevant helper T cell epitopes from antigens.
It is well known that the immune system focuses on and responds to very few representative immunodominant epitopes from invading pathogenic insults such as infectious agents and antigenic targets in autoimmune diseases, allergy and cancer 1, 2 . In each of these cases, the immune system either responds positively or, in case of cancer, fails to respond to the immunodominant epitopes in the context of MHC molecules. Recent advances in understanding of the antigen presentation pathway have shown that the steps of antigen processing and selection crucially influence the peptide repertoire presented to T cells. Thus, methods for determining MHC-restricted immunodominant epitopes would be more accurate if all of the steps preceding antigen presentation were reduced to a minimum. Various approaches have been developed to identify MHC-restricted peptides that may elicit strong T cell responses. One of these approaches uses large arrays of overlapping synthetic peptides that map the entire amino acid sequence of an antigenic protein to identify MHC-restricted peptides and, consequently, putative immunodominant epitopes. The large number of protein sequences available for mapping is now making peptidemapping experiments highly expensive, labor intensive and often unreliable. Alternative approaches based on computer-driven algorithms have also been developed to predict putative MHC-restricted binders. These algorithms use matrix-and anchor-based motifs to screen amino acid sequences of antigenic proteins.
To determine whether immunodominance is regulated during antigen processing, we designed a simple cell-free system composed of defined protein components: full-length antigen and five purified proteins (human MHC class II, HLA-DM, and cathepsins B, H and S). We tested this system successfully against two model antigens: recombinant influenza virus HA1 protein (rHA1), containing the well-characterized DR1-restricted immunodominant peptide HA 306-318 from the A/Texas/1/77 strain 3 , and CII, which is implicated in collagen-induced arthritis in mice 4 . We evaluated the reductionist system for identifying HLA-DR1-restricted unknown immunodominant epitopes with HA1 from A/Vietnam/1203/2004 (H5N1) and recombinant malaria antigen, LSA-NRC, as the new antigens. We show that the cell-free MHC class II antigen-processing system identified a single epitope from either H5N1 or LSA-NRC, which we verified in HLA-DR1-positive humans or transgenic mice as immunodominant. Thus, our system provides a unique technology for identifying the immunodominant epitopes from other unknown antigens.
antigens are taken up by antigen-presenting cells from exogenous sources and shuttled through a series of endosomal compartments. These compartments contain a denaturing environment, accessory chaperone, and proteolytic enzymes that digest protein antigens and allow binding of some peptide fragments to the groove of MHC class II molecules 5 . To recreate the MHC class II antigen processing compartment 6 , we selected a minimum number of essential components: a soluble form of the human MHC II molecule (HLA-DR1), soluble HLA-DM (DM) and cathepsins B, H and S. We included DM in the system because of its role in peptide editing 7, 8 . DM is known for catalyzing displacement of class II-associated invariant chain peptide (CLIP) and other peptides from the MHC groove, as well as for inducing peptide binding 9, 10 . DM operates by generating a peptidereceptive MHC class II, which it accomplishes by exerting conformational changes in class II-peptide complexes that prevent formation of hydrogen bonds between MHC class II and the peptide main chain 11 . By inducing MHC II to adopt a peptide-receptive conformation that can quickly sample a large pool of peptides derived from exogenously acquired proteins, DM acts as a peptide editor that might exert influence on epitope selection. Cathepsin S is the major endoprotease involved in class II antigen processing outside of the thymus and can generate smaller fragments from full-length proteins, so it was chosen as our only endoprotease 12, 13 . We chose the exopeptidases cathepsin B and cathepsin H because they are constitutively expressed in all professional antigenpresenting cells and have carboxypeptidase (cathepsin B) and aminopeptidase (cathepsin H) activities important for trimming longer fragments bound to MHC II molecules. Cathepsins B and H have endoprotease activity, as well 14 . To mimic the endosomal compartment, we included free l-cysteine 15 to aid in protein unfolding 16 . l-cysteine also helps the catalytic activity of thiol-dependent lysosomal enzymes. Because cathepsins and DM are active in acidic pH, we used citrate phosphate buffer at pH 5.
An SDS-PAGE assay showed little proteolysis of DR1 (either empty or peptide bound) by cathepsins B and H ( Fig. 1a,b ) under the conditions adopted for the digestion of rHA1 ( Fig. 1a) . Empty DR1 was susceptible to cathepsin S digestion, but peptide-bound DR1 complex was resistant ( Fig. 1b) . Soluble DM was somewhat sensitive to all three cathepsins ( Fig. 1b) . Because of the susceptibility of DM and empty DR1 to cathepsins, we preincubated antigens with DR1 and DM before the inclusion of the proteases. Once all components of the system were incubated together under endosomal-and lysosomal-like conditions, we isolated peptide-DR1 complexes by immunoprecipitation and analyzed peptides eluted from DR1 on a matrix-assisted laser desorption ionization (MALDI) mass spectrometer ( Supplementary Fig. 1 ).
rHA1 of influenza with known immunodominant epitope
We first tried using rHA1 from influenza strain A/PR/8/34, to which we genetically attached the well-defined immunodominant epitope from A/Texas/1/77-derived HA 306-318 (PKYVKQNTLKLAT) 3 Table 1 and Supplementary Fig. 2 ). Comparison of spectra of peptides eluted from DR1 versus the background that did not contain rHA1 showed rHA1-derived peptide species, several of which could be detected in the m/z 1,950-2,530 range ( Fig. 1c-f ). We determined the sequences of six out of 10 such peptide species through collision-induced dissociation (CID). Among those, four contained the immunodominant HA 306-318 epitope from influenza strain A/Texas/1/77 (at m/z 2,153.09, 2,217.27, 2,281.27 and 2,524.45) ( Fig. 1c and Supplementary Figs. 3 and 4) . The sequences of the other two peptides at m/z 2,265.09 and 2,339.09 contained INSSLPYQNIHPVITIGECPK, derived from influenza strain A/PR/8/34 ( Fig. 1c and Supplementary Figs. 5 and 6) . For the last four peptides whose sequence identification through CID posed a challenge, we conducted a search to match their masses with rHA1-derived sequences with Findpept (http://www.expasy. org/tools/findpept.html) while taking certain artifactual modifications, such as peptide oxidation or alkylation, into consideration 17, 18 . We found that the peaks at m/z 1,955.09, 2,118.00 and 2,503.18 each possibly contained peptides derived from influenza strain A/PR/8/34 ( Supplementary Table 2 ). To rule out the possibility of preexisting peptide fragments containing HA 306-318 contaminating the mixture during the preparation of rHA1 proteins, we examined the repertoire of peptides bound to DR1 in the presence or absence of the added cathepsins. We detected none of the rHA1-derived peptides without processing of protein antigens by the cathepsins (Supplementary Fig. 7) . We prepared samples that included cathepsin S in addition to cathepsins B and H ( Fig. 1e,f) . This sample reaction produced a profile nearly identical to that of the reaction containing cathepsins B and H only ( Fig. 1c) , with the exception that including cathepsins S caused elimination of rHA1derived peptides at m/z 1,955.09 and HA 298-317 (A/PR/8/34) at m/z 2,339.09 ( Fig. 1c,e ).
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We determined the immunodominance of the identified peptides in DR1-transgenic mice immunized with the rHA1 in complete Freund's adjuvant (CFA). These mice 4 express a fusion product of the peptidebinding groove of DR1 and the membrane-proximal domain of mouse MHC class II I-E. These mice express DR1 as their only MHC II 19 , as they were backcrossed to MHC class II deletion mutants for 13 generations to eliminate endogenous mouse MHC class II I-A f . We isolated draining lymph and used the cells in a recall T cell proliferation assay of increasing doses of the identified peptides, rHA1 or CLIP 89-105 as a negative control. We observed strong dose-dependent responses to HA 306-318 (A/Texas/1/77) and to the rHA1 but no response to CLIP 89-105 ( Fig. 1g ). There was a significantly lower response (two out of five mice) ( Fig. 1g ) or no response (three mice) to HA 298-317 (A/PR/8/34) ( Fig. 1h) . The sum of the proliferative responses to HA 306-318 and HA 298-317 peptides approached the magnitude of the response to the whole HA protein ( Fig. 1g) . Thus, our reductionist system was able to identify the immunodominant epitope.
CII with known immunodominant epitope
We next proceeded with another well-defined immunodominant epitope, CII. CII, a major component of cartilage, is the main suspected autoantigen in rheumatoid arthritis in DR1 + individuals. Through studies conducted on DR1-transgenic mice, CII 282-289 (FKGEQGPK) has been identified as its DR1-restricted immunodominant core epitope 4 . To recapitulate the physiological conditions in which this antigen is digested, we predigested CII with matrix metalloproteinase-9 (MMP-9) because it has been shown that CII undergoes extracellular processing first, with the resulting fragments being further processed after uptake by professional antigen-presenting cells 20 . We included MMP-9-digested CII, a test antigen, and we isolated and analyzed DR1-bound peptides. The majority of CII-derived peptide species appeared in the m/z 3,000-3,500 range ( Fig. 2a-c) . We sequenced the most prominent peak of this cluster by tandem mass spectrometry and determined it to be residues 273-305 of CII (QTGEPGIAGFKGEQGPKGEPGPAG VQGAPGPAG, underlining indicates the core CII 282-289 epitope), with four hydroxylated residues ((CII 273-305 ) 4OH ; Supplementary  Fig. 8 and Supplementary Table 3 ). The other peptides in this cluster contained the same core epitope, and they were consistent in mass with the post-translational modification variants of this peptide that would be expected to be present ( Fig. 2c) 20, 21 . A baculovirus-encoded conotoxin-like peptide (CL [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] , FAALNAQHVLA) ( Supplementary Fig. 9 ) was present at m/z ~1,153 Da. This peptide probably bound a portion of the DR1 molecules when they were initially synthesized within baculovirus-transduced insect cells ( Fig. 2a,b) 22 . As before, we immunized DR1-transgenic mice with CII protein in CFA, and we used lymphoid cells in a recall proliferation assay with CII 280-294 , the CII protein or CLIP 89-105 . We observed strong dose-dependent responses to CII 280-294 and the CII protein, whereas we saw no response to CLIP 89-105 ( Fig. 2d) .
De novo identification of T cell epitopes from rHA1 of H5N1
We next attempted de novo identification of immunodominant epitopes of HA1 protein of H5N1. The experimental set up was identical to that with the chimeric rHA1 above. We used the native or heat-denatured HA1 from the H5N1 influenza strain A/Vietnam/1203/2004 (H5N1-rHA1) as antigen. We detected two unique H5N1-rHA1-derived peptide species at m/z 1,814.82 and 2,201.00 compared to the background spectrum, regardless of whether the protein was native or heat denatured ( Fig. 3a-c) . Microsequencing identified the sequences as HA 259-274 (SNGNFIAPEYAYKIVK) ( Fig. 3d) and HA 259-278 (SNGNFIAPEYAYKIVKKGDS) ( Supplementary Fig. 10 ) at m/z 1,814.82 and m/z 2,201.00, respectively, both sharing the core 16-residue sequence (underlined). Thus, the system selected a single core epitope from intact H5N1-rHA1.
We evaluated the immunodominance of the identified peptide by its ability to induce T cell responses. We immunized DR1-transgenic mice with the H5N1-rHA1 in CFA. We used the lymphoid cells in recall proliferation and cytokine production assays with increasing doses of HA 259-274 , CLIP 89-105 or H5N1-rHA1. We observed strong dosedependent proliferation responses to HA 259-274 and H5N1-rHA1 but not CLIP 89-105 ( Fig. 4a) . Proliferation in response to HA 259-274 was strikingly similar in magnitude to the response elicited by the whole H5N-rHA1 ( Fig. 4a) . Interleukin-2 (IL-2) production in response to H5N1-rHA1 was greater than that in response to HA 259-274 at 24 h, but its production reached similar levels to H5N1-rHA1 at 48 h (Fig. 4b) . Overall, we detected a significantly higher amount of interferon-γ (IFN-γ) production in comparison to IL-2, as determined by ELISA (Fig. 4b,c) . IFN-γ production in response to stimulation by the H5N1-rHA1 and by the HA 259-274 was similar in magnitude both at 48 h and at 72 h (Fig. 4c) .
We immunized DR1-transgenic mice with either the H5N1-rHA1 in CFA or CFA alone. We stained freshly isolated lymphoid cells with HA 259-274 -DR1 or CLIP-DR1 tetramers and antibodies to CD4 and CD44 (activation marker) ( Fig. 4d and Supplementary Fig. 11 ). Cells positive for HA 259-274 -DR1 tetramer comprised ~0.01% of the CD4 + CD44 + population in the control group versus ~0.1% among cells isolated from mice immunized with H5N1-rHA1-CFA. After a 7-d in vitro expansion with H5N1-rHA1, the HA 259-274 -DR1 tetramerpositive population comprised nearly 3% of the CD4 + CD44 + population ( Fig. 4e and Supplementary Fig. 12 ). In all, in vitro stimulation with the H5N1-rHA1 for 7 d resulted in enrichment of HA 259-274 -specific CD4 + CD44 + T cells. These combined results from proliferation assays, cytokine measurements and tetramer staining indicate that the reductionist system identified a major T cell epitope that activates CD4 + T cells specific for H5N1-rHA1.
Detection of T cell epitopes from a malaria antigen
Plasmodium falciparum liver-stage antigen 1 (LSA-1) is exclusively expressed in malaria-infected hepatocytes at a preerythrocytic stage. LSA-1 contains a large central 17-amino-acid repeat region flanked by two highly conserved N-and C-terminal regions shown to contain B and T cell-stimulating epitopes 23, 24 . LSA-NRC, a modified recombinant form of LSA-1, was designed as a vaccine against preerythrocyte stage malaria 25 (Supplementary Table 4) .
We incubated LSA-NRC with DR1 and DM followed by cathepsins B, H and S. We eluted the peptides from DR1 and analyzed them by mass spectrometry. Comparing the spectra of experimental and background groups, we detected five unique peptide species at m/z ~1,747, 1,877, 2,278, 2,295 and 3,475 (Fig. 5a,b) and determined their sequences by CID. The sequence of the peptides at m/z ~1,747 and 1,877 were LSA 325-338 (YDNFQDEENIGIYK) (Supplementary Fig. 13) (d) Draining lymph node cells (pooled from four mice) freshly isolated from H5N1 rHA1 protein-immunized mice on day 8 and directly stained for T cells specific for HA 259-274 -DR1 or CLIP-DR1. Cells from three mock-immunized mice were also stained for the presence of T cell receptors specific for HA 259-274 -DR1 and served as controls. Cells were stained for 2 h at 37 °C with varying concentrations of tetramers as shown followed by staining with monoclonal antibodies for CD4, CD8, CD44, F4/80 and B220. (e) Cells from d were expanded with 0.07 μM H5N1 rHA1 for an additional 7 d in vitro. Protein-stimulated cells were stained with the tetramers (1.5 μg ml −1 ) and the antibodies described in d. Numbers represent the percentage of tetramer-positive events among parent CD4 + (CD4 + CD44 + CD8 − F4/80 − B220 − 7AAD − ) cells. t e c h n i c a l r e p o r t s respectively. The peptides at m/z ~2,278 and 2,295 were posttranslation modification variants of a single peptide, LSA 434-453 (EDITKYFMKLGGSGSPHHHH) (Fig. 5c) , with its methionine residue either unmodified or oxidized (16-Da difference). Although the intensity of peptide peak at m/z ~3,475 was weak and indistinguishable from the background, fragmentation data determined its sequence to be LSA 197-226 (LPSENERGYYIPHQSSLPQDNRGNS RDSKE) ( Fig. 5b) . In vivo verification in DR1-transgenic mice confirmed LSA 436-449 as immunodominant by T cell proliferation and IL-2 and IFN-γ production (Fig. 5d,e and Supplementary Fig. 14) . We also used two peptides from the library of peptides originally synthesized as potentially active on the basis of conventional 15-mer overlapping peptide library design. The two peptides were LSA 323-337 (VQYDNFQDEENIGIY) and LSA 429-443 (VDELSEDITKYFMKL), which we specifically chose because they contain partial sequences from the epitopes selected by our reductionist system (underlined). Those two peptides did not recall any responses (Fig. 5d,e and Supplementary Fig. 14) .
To confirm the potential clinical utility of this system, we used donor-derived T cells from human volunteers who, as part of a malaria vaccine trial, had been immunized twice with LSA-NRC in a liposome-based formulation 26 . We tested samples from eight individuals whose CD4 + T cells had responded vigorously to the LSA protein in vitro. We obtained peripheral blood mononuclear cells (PBMCs) before immunization and after a second immunization with LSA-NRC. We used these PBMCs for proliferation by stimulation in vitro with various concentrations of LSA 436-449 , CLIP 89-105 and LSA-NRC. We found that whereas all eight post-immunization samples responded to LSA protein, only two individuals (subject 8013 and subject 2060) responded vigorously to our epitope, and none responded to CLIP 89-105 stimulation. HLA-DRB1 typing revealed that the two responding samples to the LSA 436-449 epitope came from DR1 + individuals (DR B1*0101) (Fig. 5f) . The six nonresponding samples were from DR1 − individuals carrying DR4, DR8, DR11, DR12, DR13, DR14, DR15 or DR17 variants. These results indicate that LSA 436-449 is a DR1-restricted epitope, consistent with the fact that the reductionist system used to identify this epitope used DR1. Notably, these results demonstrate that the reductionist system is capable of predicting epitopes that human T cells recognize.
DISCUSSION
We have established a reductionist antigen processing system composed of DR1, DM and cathepsins B, H and S that identifies physiologically relevant immunodominant epitopes. We confirmed immunodominance in immunized DR1-transgenic mice and in humans. We confirmed the immunodominance of de novo epitopes of H5N1-rHA1 or LSA-1 by virtue of their capacity to induce T cell activation at levels similar to that induced by the whole proteins. Our results suggest that immunodominance is dictated by the combined interplay of cathepsins, HLA-DM and MHC II during antigen processing.
The finding that so few components of MHC II antigen processing can process full-length antigens and yield the physiologically selected immunodominant epitopes from protein antigens is notable. In addition to DM, the cell-free system relies on endo-and exopeptidases. We find that the inclusion of cathepsin S alone, in the absence of the C-and N-terminal exopeptidases used in the system, was not adequate for successful detection of the dominant epitopes in rHA1 (data not shown). In contrast, a combination of cathepsins B, H and S was sufficient for all four antigens studied here. Cathepsins B and H in the absence of cathepsin S led to the capture of HA 306-318 and HA 298-317 from our model influenza antigen. There has been little appreciation for the roles of the exopeptidases, cathepsin B and cathepsin H, in antigen processing. Cathepsin B-deficient mice have been shown not to have any major defects in antigen processing 27 . Also, little information, if any, is available regarding a role for cathepsin H in antigen processing. As such, it was quite unexpected that the combined use of cathepsins B and H led to the proper processing of protein antigens and the selection of immunodominant epitopes, whereas the presence or absence of cathepsin S did not change the overall outcome of epitope selection for rHA1 from the A/Texas1/77 strain. Thus, we here define a new key role for cathepsin H in conjunction with cathepsin B.
Our system relies on mass spectrometry for identifying epitopes, a technology that has been previously used for characterizing antibody epitopes 28 and for studying MHC-associated peptides [29] [30] [31] . Being so precise, mass spectrometry has the advantage of having the capacity of identifying post-translationally modified epitopes. Post-translational modification of antigenic peptides, specifically citrullination, has been shown to be crucial in activation of CD4 + and CD8 + T cells by MHC II 32 and MHC I 33 , respectively. Because our assay uses actual protein antigens, it intrinsically takes into account the effects that post-translational modifications may have on epitope selection.
In summary, we have established a cell-free antigen processing system that can successfully identify immunodominant epitopes from protein antigens that are recognized by CD4 + T cells from immunized HLA-DR1-expressing humans and mice. Although in this report we have presented data with only HLA-DR1, the system can be expanded to other MHC class II alleles and can be developed into a high-throughput screening system. Our observations indicate that this system closely mimics antigen processing in vivo. If used for application purposes, the system would help to reduce cost and increase effectiveness in determining immunodominant epitopes of antigens from infectious agents, autoimmune antigens and cancer. The identified epitopes can be incorporated into MHC class II multimers 34 for detection of T cells reactive to the epitopes as correlates of immunity for diagnosis and/or monitoring disease progression in humans. Finally, this system can be used in the design of peptide vaccines or for evaluation of proper recombinant vaccine designs before human trial studies to ascertain that artifacts, such as additional sequences not present naturally, introduced to the recombinant vaccines do not interfere with the recognition of the wild-type epitopes.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
Note: Supplementary information is available on the Nature Medicine website. t e c h n i c a l r e p o r t s
